|
|
Post by lanzapaste on Aug 6, 2014 16:02:14 GMT
Cytori Therapeutics (CYTX -20%) places patient enrollment on clinical hold in its Athena and Athena II studies evaluating the safety and feasibility of adipose-derived regenerative cells (ADRCs) in heart failure patients with ischemic heart disease who are already receiving maximal therapy with no options for revascularization.
The hold will be in effect while investigators review cerebrovascular events that occurred in three patients. The symptoms did not appear in earlier trials and could be the result of the patients' co-morbidities.
Because of the time required to fully investigate the adverse events, the company does not now believe that it will complete enrollment in the Athena trial prior to the end of 2014.
-20.48% $1.67pps
|
|
|
|
Post by JHam on Aug 6, 2014 16:20:07 GMT
Cytori Therapeutics (CYTX -20%) places patient enrollment on clinical hold in its Athena and Athena II studies evaluating the safety and feasibility of adipose-derived regenerative cells (ADRCs) in heart failure patients with ischemic heart disease who are already receiving maximal therapy with no options for revascularization. The hold will be in effect while investigators review cerebrovascular events that occurred in three patients. The symptoms did not appear in earlier trials and could be the result of the patients' co-morbidities. Because of the time required to fully investigate the adverse events, the company does not now believe that it will complete enrollment in the Athena trial prior to the end of 2014. -20.48% $1.67pps Adipose cells. Why am I not surprised. Sad news for patients. Hopefully they didn't worsen their condition due to this treatment. |
|
|
|
Post by lanzapaste on Sept 22, 2014 20:25:50 GMT
Is there a bounce coming soon or is this a slow, painful death playing out? SEPT 22/14 Close @ 0.87 Market cap approx $76M In company news, Cytori Therapeutics ( CYTX ) tumbled to a new record low Monday after the biotech company announced plans to consolidate and restructure its operations, including plans to reduce its workforce by around 35%. The company said it plans to soon trim around 42 employees from a peak of 119 earlier this year, expecting to take a one-time restructuring expense or around $500,000. It also said despite the expected cut-backs, the company should post "modest" revenue growth this year compared with year-ago levels, likely continuing into 2015 and 2016, but showing positive margin contributions starting next year. CYTK shares were down about 12% at 88 cents a share, earlier sliding to a new, all-time low of 85 cents a share. Over the past 12 months, the stock has fallen nearly 60% prior to today's slide. Read more: www.nasdaq.com/article/sector-update-health-care-stocks-ending-moderately-lower-cytori-cutting-jobs-takes-500000-restructuring-charge-cm393612#ixzz3E4tdAnjU |
|
